Entrada Therapeutics, Inc. (NASDAQ:TRDA) People
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Mary Thistle Other companies: Aktis Oncology, Inc. (Independent Director · Since at least Jan 8, 2026); Cullinan Therapeutics, Inc. (Chair of the Compensation Committee · Since at least Aug 8, 2024); Vigil Neuroscience Inc (Director · Since at least Apr 18, 2022); Q32 Bio Inc. (Director · Since at least Mar 27, 2018); Alaunos Therapeutics, Inc. (Director · Nov 15, 2020 – Jun 6, 2023 · Past); Dimension Therapeutics (Chief Operating Officer · Feb 1, 2017 – Nov 7, 2017 · Past) | Industry Leader and Independent Director · Since at least Oct 28, 2021 |
| John F Crowley Other companies: Intellia Therapeutics, Inc. (Director · Oct 2, 2020 – Jun 14, 2023 · Past); Amicus Therapeutics Inc (Executive Chairman, Director · Dec 31, 2011 – Mar 1, 2024 · Past) | Director · Oct 28, 2021 – Jun 8, 2023 · Past |
| Maha Radhakrishnan Other companies: Candel Therapeutics, Inc. (Director · Since at least Jun 4, 2025); Alto Neuroscience, Inc. (Director · Mar 8, 2024 – Mar 8, 2024 · Past) | Industry Leader and Independent Director · Since at least Jun 1, 2025 |
| Nerissa Kreher Other companies: Xeris Biopharma Holdings, Inc. (Independent, Non-executive Board Member · Since at least Jun 30, 2026); Rezolute, Inc. (Board Member · Since at least Jun 23, 2022) | Chief Medical Officer · Jul 1, 2022 – Sep 1, 2023 · Past |
| Dipal Doshi Other companies: Azenta, Inc. (Director · Since at least Jan 30, 2025) | Chief Executive Officer · Since at least Jun 27, 2022 |
| Gina Chapman Other companies: CARGO Therapeutics, Inc. (President & CEO, Director · Nov 9, 2023 – Mar 14, 2025 · Past) | Industry Leader and Independent Director · Since at least Sep 1, 2023 |
| Kory Wentworth Other companies: Bluebird bio Inc (Principal Accounting Officer · Dec 18, 2017 – Aug 3, 2020 · Past) | Chief Financial Officer · Since at least Oct 28, 2021 |
| Bernhardt Zeiher | Industry Leader and Independent Director · Since at least May 21, 2026 |
| Caileigh Dougherty | Head of Investor Relations & Corporate Communications · Mar 24, 2025 – Nov 4, 2026 · Past |
| ContactCaileigh DoughertyHead | of Investor Relations & Corporate · Feb 3, 2025 – Nov 4, 2026 · Past |
| Doug Snow | Head of Investor Relations · Since at least Oct 21, 2026 |
| Jared Cohen | General Counsel · Since at least Nov 5, 2026 |
| Karla MacDonald | Chief Corporate Affairs Officer · Since at least May 6, 2026 |
| Kevin Healy | Senior Vice President, Regulatory Affairs · Since at least Nov 5, 2026 |
| Kush M. Parmar | Managing Partner, 5am Ventures (Board Chairman) · Since at least Jun 11, 2025 |
| Linea Aspesi | Chief People Officer · Since at least Oct 21, 2026 |
| Natarajan Sethuraman | President of Research and Development · Since at least Oct 28, 2021 |
| Nathan J. Dowden | President and Chief Operating Officer · Since at least Sep 3, 2026 |
| Peter S. Kim | Virginia and D.K. Ludwig Professor of Biochemistry, Stanford University · Since at least Oct 28, 2021 |